Gastric cancer, noted for its high mortality rates worldwide, is typified by an insidious ability to both proliferate aggressively and subvert immune defenses. Central to this evasion is the tumor microenvironment, a complex network of cellular crosstalk and signaling pathways. Despite extensive investigation, the exact molecular mechanisms that promote tumor-associated macrophage (TAM) polarization towards a pro-tumor, immunosuppressive phenotype, and the subsequent functional exhaustion of cytotoxic CD8+ T cells, have remained elusive.

Leveraging the expansive data repository of The Cancer Genome Atlas (TCGA), the researchers initially identified that SULF1 expression is markedly elevated in gastric cancer tissues compared to normal gastric epithelium. Notably, this upregulation correlates strongly with advanced tumor stages and poor overall patient survival, suggesting that SULF1 could serve as both a prognostic biomarker and an active contributor to disease progression rather than a mere bystander.

To translate these bioinformatic findings into functional insights, Lu and Lu employed CRISPR/Cas9 gene editing alongside lentiviral-mediated gene overexpression to modulate SULF1 levels in gastric cancer cell lines. Cells with suppressed SULF1 expression displayed significantly reduced proliferation, migration, and invasion capacities, coupled with enhanced apoptotic rates. In stark contrast, augmenting SULF1 levels amplified malignant behaviors, underscoring the protein’s direct pro-tumorigenic influence.

Beyond tumor cell intrinsic effects, the investigation delved into SULF1’s role in orchestrating immune cell dynamics within the tumor niche. Co-culture experiments involving human macrophages exposed to conditioned media from SULF1-overexpressing gastric cancer cells revealed induction of the M2 macrophage polarization phenotype, characterized by immune suppression and tissue remodeling functions that typically facilitate tumor progression.

In parallel, CD8+ T cells subjected to the same experimental conditions exhibited hallmark features of exhaustion—a dysfunctional state manifesting as reduced cytokine production, diminished cytotoxic granule release, and impaired proliferative capacity. Flow cytometric analyses quantitatively confirmed that elevated SULF1 prompts a shift in T cell functionality towards this exhausted phenotype, a major barrier to effective anti-tumor immunity.

Sifting through intracellular signaling pathways, the study highlighted the STAT3 pathway as a critical mediator of SULF1’s immunomodulatory activities. Biochemical assays, including immunoblotting and nuclear translocation evaluations, revealed that SULF1 activates STAT3 signaling within macrophages. This activation drives M2 polarization and subsequently fosters an immunosuppressive milieu capable of blunting cytotoxic T cell responses.

A particularly striking component of the research involved in vivo validation using murine models of gastric cancer. Silencing SULF1 in tumor cells implanted into mice led to pronounced tumor regression accompanied by reduced markers of T cell exhaustion within the tumor microenvironment. Conversely, exogenous supplementation of secreted SULF1 protein reinstated the immunosuppressive conditions and accelerated tumor growth, cementing the causal role of SULF1 in shaping tumor immunity.

The implications of these findings are profound. They position SULF1 not only as an oncogenic factor intrinsic to gastric cancer cells but as a potent architect of the tumor microenvironment’s immune landscape, pivoting the balance towards immune escape and tumor sustenance. This dual action opens exciting therapeutic possibilities to disrupt this deleterious axis.

Currently, immunotherapies targeting exhausted T cells, such as immune checkpoint inhibitors, are limited by the complex suppressive networks imposed by TAMs and other stromal components. By targeting the SULF1-STAT3 signaling circuit, it may be possible to reprogram macrophages away from their M2 state and restore CD8+ T cell activity, thereby sensitizing tumors to existing and emerging immunotherapeutic regimens.

Additionally, the study’s integration of multi-dimensional experimental approaches—from genome-wide data mining to precise gene editing, immune cell functional assays, and in vivo modeling—exemplifies an innovative paradigm for unraveling the tumor-immune interface. The comprehensive elucidation of SULF1’s role offers an archetype for similar molecular dissection in other cancer types exhibiting immune evasion.

Beyond gastric cancer, the secreted nature of SULF1 suggests it might also modulate systemic immune responses, potentially influencing metastatic niches or distant immune organs. Future investigations exploring SULF1 expression patterns across cancers and its systemic immunological impact could broaden its relevance as a clinical target.

In summary, Lu and Lu’s research delivers compelling evidence that secreted SULF1 protein is a key orchestrator of tumor immune evasion in gastric cancer, primarily through activation of STAT3-dependent macrophage polarization and consequent CD8+ T cell exhaustion. Their work not only refines our molecular understanding of tumor-host immune dynamics but also ushers in novel strategies for enhancing anti-tumor immunity by disrupting this newly characterized axis.

As gastric cancer continues to pose significant clinical challenges with limited therapeutic responsiveness, targeting the SULF1-STAT3 pathway emerges as an alluring, innovative strategy. This discovery spotlights a critical mechanistic node ripe for drug development, with the potential to improve patient outcomes by reinvigorating immune-mediated tumor control and curtailing cancer progression.

The confluence of molecular biology, immunology, and clinical oncology in this work underscores the transformative power of interdisciplinary approaches in cancer research. Looking forward, incorporation of SULF1-targeted therapies with existing treatment modalities may herald a new era of precision immuno-oncology in gastric cancer and beyond, catalyzing durable remissions and enhanced survival for affected patients.

Subject of Research: Gastric cancer immunology, tumor microenvironment, SULF1 regulation, macrophage polarization, CD8+ T cell exhaustion, STAT3 signaling

Article Title: Secreted SULF1 protein modulates CD8+ T cell exhaustion by promoting TAM polarization in gastric cancer

Article References:
Lu, X., Lu, D. Secreted SULF1 protein modulates CD8 + T cell exhaustion by promoting TAM polarization in gastric cancer. Genes Immun (2026). https://doi.org/10.1038/s41435-026-00399-x

Image Credits: AI Generated

DOI: 10.1038/s41435-026-00399-x (15 April 2026)

At the heart of the TME’s complexity lies the dual nature of ferroptosis: it is both a weapon against malignant cells and a modulator of immune function. Cytotoxic CD8⁺ T cells are now known to potentiate antitumor activity by releasing interferon-gamma (IFN-γ), which downregulates the system xc^– cystine/glutamate antiporter in cancer cells, thereby depleting glutathione (GSH)—a key antioxidant. This depletion sensitizes tumor cells to ferroptosis, revealing a novel immunological mechanism of tumor suppression. Moreover, IFN-γ influences the phenotype of tumor-associated macrophages (TAMs), driving their transformation toward the pro-inflammatory M1 subtype that supports tumor eradication and impedes cancer progression.

Conversely, immune cells themselves are not impervious to ferroptosis within the TME. CD8⁺ and CD4⁺ T cells exhibit lipid peroxidation under conditions of impaired glutathione peroxidase 4 (GPX4) activity or exposure to ferroptosis inducers like RSL3, resulting in compromised immune function. Strikingly, overexpression of protective proteins such as GPX4 and ferroptosis suppressor protein 1 (FSP1) shields these lymphocytes from ferroptotic death. These insights underscore the delicate balance wherein immune cells navigate oxidative stress—not merely as bystanders but as active participants whose survival directly impacts antitumor immunity.

Regulatory T cells (Tregs), notorious for suppressing immune responses, also intertwine with ferroptosis pathways. In the absence of GPX4, Tregs demonstrate heightened ferroptotic sensitivity, leading to the secretion of pro-inflammatory cytokines such as IL-1β, which paradoxically facilitates the expansion of tumor-promoting T helper 17 (Th17) cells. This phenomenon illustrates how ferroptosis modulation within Tregs could recalibrate the immunosuppressive landscape of the TME; however, the therapeutic challenge remains to selectively target tumor-infiltrating Tregs without unleashing systemic autoimmunity.

B cells, especially the marginal zone and B1 subsets, have recently been implicated in ferroptotic regulation within tumors. These cells’ reliance on fatty acid uptake through scavenger receptors like CD36 predisposes them to lipid peroxide accumulation and ferroptosis when GPX4 activity wanes. The metabolic reprogramming intrinsic to their survival and function adds a further layer of complexity, suggesting that ferroptosis not only shapes lymphocyte fate but also influences humoral responses in cancer contexts.

Dendritic cells (DCs), vital for antigen presentation and T cell activation, are vulnerable to ferroptotic damage wrought by oxidative stress and lipid peroxidation by-products. This accumulation triggers endoplasmic reticulum stress and engages transcriptional programs such as the X-box binding protein 1 (XBP1) pathway, undermining DCs’ immunostimulatory capacity. Intriguingly, ferroptosis in DCs can be mitigated by blocking peroxisome proliferator-activated receptor gamma (PPARγ), opening avenues to preserve their tumor-fighting potential in the oxidative TME milieu.

Macrophages within tumors exhibit a fascinating interplay between polarization states and ferroptosis susceptibility. While immunosuppressive M2 macrophages display sensitivity to ferroptosis inducers, the classically activated M1 subset resists ferroptosis via inducible nitric oxide synthase (iNOS)-mediated nitric oxide production that counteracts lipid peroxide formation. Inducing ferroptosis in TAMs can reprogram M2 macrophages into M1-like phenotypes, facilitating antitumoral immunity and providing a promising therapeutic strategy. Emerging nanoparticle-based ferroptosis inducers have demonstrated capacity to harness this phenotype switch, igniting robust phagocytic activity and inhibiting metastatic dissemination.

Natural killer (NK) cells, crucial innate effectors, face ferroptotic threats primarily through lipid peroxidation triggered by tumor metabolites like L-Kynurenine. This lipid oxidative stress impairs NK cell glycolysis—a metabolic pathway essential for their cytotoxic function. Protective factors such as GPX4 overexpression and nuclear factor erythroid 2–related factor 2 (NRF2) activation can rescue NK cells from ferroptosis and restore their antitumor efficacy. These mechanistic insights provide a foundation for enhancing NK cell resilience in hostile tumor niches.

Myeloid-derived suppressor cells (MDSCs), particularly polymorphonuclear subsets, undergo spontaneous ferroptosis in the TME due to heightened oxidative stress and GPX4 downregulation. While ferroptosis reduces MDSC numbers, the release of immunosuppressive lipid mediators like prostaglandin E2 (PGE2) following cell death paradoxically hinders antitumor T cell activity and supports TAM-mediated immune evasion. Thus, ferroptosis in MDSCs presents a double-edged sword, demanding nuanced therapeutic interventions that consider downstream immunomodulatory effects.

Cancer-associated fibroblasts (CAFs) contribute substantially to tumor resistance against ferroptosis by supplying antioxidant molecules such as GSH and cysteine. This metabolic support disrupts ferroptotic cascades in cancer cells, shielding tumors from cell death. Notably, CD8⁺ T cell-derived IFN-γ counteracts CAF-mediated protection by inducing γ-glutamyltransferase 5 (GGT5) expression, which degrades extracellular GSH and curtails antioxidant availability. Concurrently, IFN-γ suppresses the tumor’s system xc^– expression via JAK/STAT signaling, intensifying tumor vulnerability to ferroptosis. This interplay exemplifies the tug-of-war between cancer cells, stromal components, and immune effectors within the ferroptotic landscape.

Collectively, the dynamic interactions between ferroptosis and the multifarious cell types within the TME underscore an intricate regulatory network with profound implications for cancer biology. Therapeutic approaches leveraging ferroptosis must, therefore, consider impacts not only on tumor cells but also on immune and stromal compartments that critically modulate antitumor immunity. Targeted induction of ferroptosis in tumor cells combined with preservation or restoration of immune cell function holds promise for next-generation cancer therapies.

The emerging paradigm situates ferroptosis as a nexus connecting metabolic reprogramming, oxidative stress, and immune regulation. Beyond its cytotoxic role, ferroptosis shapes the immunological milieu, influencing antigen presentation, immune cell polarization, and cytokine milieu, thereby dictating either tumor suppression or progression. Enhancing our mechanistic understanding will facilitate the design of precision interventions that harness ferroptosis within the immune contexture of tumors.

Future research priorities include developing selective ferroptosis modulators capable of discriminating between pro-tumorigenic and anti-tumorigenic cell populations, optimizing delivery systems such as ferroptosis-inducing nanoparticles, and integrating ferroptosis-targeted therapies with immune checkpoint blockade. Additionally, deeper insights into metabolic dependencies that predispose immune subsets to ferroptotic death will enable strategies to bolster immune resilience amidst TME oxidative challenges.

In sum, ferroptosis transcends its traditional role as a form of cell death to emerge as a pivotal orchestrator within the tumor-immune ecosystem. Its dualistic nature—as a facilitator of tumor cell demise and a determinant of immune cell viability—presents both opportunities and obstacles in the quest to reprogram the TME toward tumor eradication. As our knowledge base expands, ferroptosis promises to unlock novel frontiers in oncology, heralding transformative advances in immunometabolic cancer therapy.

Subject of Research:
Ferroptosis and its complex role within the tumor microenvironment, focusing on interactions between immune cells and cancer cells in esophageal cancer.

Article Title:
Exploring the role of ferroptosis in esophageal cancer: mechanisms and therapeutic implications.

Article References:
Zhao, D., Li, W., Han, Z. et al. Exploring the role of ferroptosis in esophageal cancer: mechanisms and therapeutic implications. Cell Death Discov. 11, 405 (2025). https://doi.org/10.1038/s41420-025-02696-2

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02696-2